“ADHD and autism are being overdiagnosed in children and young adults.”

• A systematic scoping review of 334 studies (Kazda et al., JAMA Network Open, 2021) applied a formal five-question overdiagnosis framework and concluded the evidence is consistent with overdiagnosis and overtreatment of ADHD in children and adolescents, particularly for those with milder symptoms, where harms of labelling and medication may outweigh benefits.
• Relative-age effects provide hard quasi-experimental evidence of diagnostic error: in a US cohort of >400,000 children (Layton et al., NEJM, 2018), children born in August in states with a September 1 school cut-off were about 34% more likely to be diagnosed with and treated for ADHD than children born in September — i.e., normal immaturity is being coded as disorder.
• Population symptom levels have not tracked diagnosis rates. A Swedish twin-register study (Lundström et al., BMJ, 2015) found the prevalence of autism *symptoms* in children was essentially stable over a decade while registered clinical autism diagnoses rose sharply, implicating administrative/diagnostic expansion rather than a real increase in the condition.
• A meta-analysis of 11,000+ participants (Rødgaard, Mottron et al., JAMA Psychiatry, 2019) found effect sizes separating autistic from non-autistic people on cognitive and behavioural measures shrank by roughly 45–80% between 1966 and 2019, consistent with the diagnostic category being progressively broadened to include less distinct cases.
• Diagnosis rates have risen steeply in a short time: US CDC/NSCH data show ADHD diagnoses in children rose to about 11.4% (≈7.1 million) by 2022, and CDC ADDM autism prevalence rose from 1 in 150 (2000 birth-cohort surveillance) to about 1 in 31 eight-year-olds (2022 surveillance year) — increases far faster than any plausible change in underlying biology.
• UK primary-care cohort data (Russell et al., J Child Psychol Psychiatry, 2022) recorded an increase of roughly 787% in recorded autism diagnoses between 1998 and 2018, with the steepest rises in adults and females — a pattern that can reflect either correction of past under-recognition or threshold creep, and that critics read as the latter.
• Wide unexplained variation between countries, states, schools and individual clinicians in diagnosis rates for both conditions indicates that thresholds are being applied inconsistently, which is a recognised marker of diagnostic inflation at the margins.

• Community-based prevalence of ADHD (measured by standardised assessment rather than clinical records) has been stable at roughly 5–7% of children for three decades (Polanczyk et al., Int J Epidemiol, 2014); the World Federation of ADHD International Consensus Statement (Faraone et al., 2021) explicitly concludes that ADHD is *not* overdiagnosed as a whole and remains under-identified and undertreated in many countries, with rising diagnosis rates largely closing the gap toward true prevalence.
• Documented underdiagnosis in specific groups cuts directly against a blanket claim: girls and women, adults, people with intellectual disability, and historically Black, Hispanic and low-income children have been systematically diagnosed later or missed, with 'camouflaging' well documented in autistic females.
• Service data suggest unmet, not excess, demand: ADHD and autism assessment waiting lists in the UK run to hundreds of thousands of people with multi-year waits, prompting NHS England to convene an ADHD taskforce; NICE guidance (NG87) continues to warn about under-recognition as well as inappropriate diagnosis.
• Much of the autism increase is attributable to documented non-clinical factors — DSM criteria broadening (DSM-III-R, DSM-IV, DSM-5), diagnostic substitution away from intellectual disability and language disorder labels, mandated school screening, and service-eligibility incentives — which CDC itself cites as explanations for prevalence change rather than evidence that diagnosed children do not have the condition.
• The 2022 ADDM data show roughly 40% of identified autistic 8-year-olds also have intellectual disability and a further large share borderline range, indicating the diagnosed population is not simply an influx of trivially affected children.
• 'Overdiagnosis' has a technical meaning — diagnosing people who cannot benefit — and that is hard to demonstrate for neurodevelopmental conditions: most diagnosed children show functional impairment, and diagnosis is the gateway to educational accommodations and treatment with documented short-term benefit. The Lancet Commission on autism (Lord et al., 2022) frames the central problem as poor access to appropriate, personalised care globally, not surplus diagnosis.
• The scientific literature is genuinely split, and the strongest overdiagnosis findings are qualified: Kazda et al. themselves limit their conclusion to milder cases and call the overall evidence incomplete, while finding no evidence of overdiagnosis in severe presentations. No authoritative body has endorsed the unqualified statement that these conditions are overdiagnosed.

72/100 — the lab’s own confidence in the score above, not a second reading of the claim.

JAMA Network Open (Kazda et al., Overdiagnosis of ADHD in Children and Adolescents: A Systematic Scoping Review)journal · 92 · New England Journal of Medicine (Layton et al., ADHD and Month of School Enrollment)journal · 95 · The BMJ (Lundström et al., Autism phenotype versus registered diagnosis in Swedish children)journal · 92 · JAMA Psychiatry (Rødgaard, Mottron et al., Temporal Changes in Effect Sizes of Studies Comparing Individuals With and Without Autism)journal · 90 · Neuroscience & Biobehavioral Reviews (Faraone et al., World Federation of ADHD International Consensus Statement)journal · 88 · International Journal of Epidemiology (Polanczyk et al., ADHD prevalence estimates across three decades)journal · 88 · The Lancet (Lord et al., Lancet Commission on the future of care and clinical research in autism)journal · 90 · Journal of Child Psychology and Psychiatry (Russell et al., Time trends in autism diagnosis over 20 years)journal · 85 · Journal of Clinical Child & Adolescent Psychology (Danielson et al., ADHD prevalence among U.S. children and adolescents in 2022)journal · 85 · U.S. Centers for Disease Control and Prevention — Autism Data and Statistics (ADDM Network)gov · 92 · U.S. Centers for Disease Control and Prevention — ADHD Data and Statisticsgov · 92 · National Institute for Health and Care Excellence (UK), Guideline NG87: ADHD diagnosis and managementgov · 90

• Diagnosed prevalence has risen rapidly, which is compatible with at least some overdiagnosis: CDC reports ADHD diagnosis among U.S. children has increased, and CDC ADDM surveillance reports autism prevalence among 8-year-olds rising to about 1 in 31 in 2022. Rising prevalence alone does not prove overdiagnosis, but it is a key reason the concern exists.
• For ADHD specifically, a JAMA Network Open systematic scoping review concluded there is evidence consistent with overdiagnosis and overtreatment in children and adolescents, especially identification of milder/borderline cases that may receive labels and medication without clear net benefit.
• ADHD diagnoses show a relative-age effect: children who are among the youngest in their school grade are more likely to be diagnosed and treated for ADHD than older classmates, suggesting some normal immaturity may be medicalized as ADHD.
• For autism, part of the apparent prevalence increase is attributable to changing diagnostic/reporting practices rather than a true increase in underlying incidence. JAMA Pediatrics research in Denmark estimated that changes in reporting practices explained a large share of the observed increase, and a JAMA Psychiatry meta-analysis found decreasing measured differences between autistic and non-autistic groups over time, consistent with broadened diagnostic boundaries.

• The claim overstates what the evidence can show. Increased diagnosis is not the same as overdiagnosis: it can reflect better screening, broader awareness, reduced stigma, improved access to evaluations, and recognition of previously missed groups.
• Autism evidence is weaker than ADHD evidence. Diagnostic broadening and substitution show that prevalence statistics changed, but they do not by themselves prove that children or young adults are being incorrectly diagnosed.
• Underdiagnosis and delayed diagnosis still coexist with possible overdiagnosis. CDC autism surveillance emphasizes the importance of early identification and shows substantial variation by site and demographic group, indicating access and ascertainment differences rather than a simple nationwide pattern of excessive diagnosis.
• For ADHD, professional guidelines require symptoms causing impairment in more than one setting and evaluation for alternative explanations. Poor-quality or borderline diagnoses occur, but guideline-concordant diagnosis is intended to avoid labeling normal childhood behavior as ADHD.
• The statement lumps together ADHD and autism and applies broadly to children and young adults. The strongest evidence supports possible ADHD overdiagnosis in specific contexts, while autism data more strongly support changing recognition and criteria, with both overdiagnosis and underdiagnosis possible depending on population and setting.

80/100 — the lab’s own confidence in the score above, not a second reading of the claim.

JAMA Network Openjournal · 92 · BMJjournal · 91 · Centers for Disease Control and Preventiongov · 90 · American Academy of Pediatrics / Pediatricsjournal · 91 · Centers for Disease Control and Preventiongov · 90 · CDC Morbidity and Mortality Weekly Reportgov · 90 · JAMA Pediatricsjournal · 92 · JAMA Psychiatryjournal · 90

• A 2021 systematic scoping review published in JAMA Network Open found convincing evidence of ADHD overdiagnosis in children and adolescents, warning that mild symptoms are increasingly medicalized, leading to unnecessary interventions.
• Studies consistently demonstrate a 'relative age effect' in ADHD diagnoses. Children who are the youngest in their classroom cohort are significantly more likely to be diagnosed and medicated than their oldest peers, suggesting that normal developmental immaturity is sometimes being pathologized.
• For autism, some researchers argue that the broadening of diagnostic criteria (such as the transition to the DSM-5) has led to 'diagnostic inflation,' wherein individuals with very mild traits are labeled with ASD, blurring the boundaries between neurodivergence and typical development.

• The broader medical consensus attributes much of the rising prevalence in both ADHD and ASD to improved screening tools, reduced stigma, better public awareness, and the deliberate broadening of criteria to capture individuals who were historically missed, rather than false positives.
• Blanket claims of overdiagnosis obscure the profound, systemic underdiagnosis of both conditions in specific demographics, particularly girls, adult women, and racial or ethnic minorities, whose symptoms often present differently or are heavily masked.
• Recent CDC data indicates that the rising rates of autism reflect a closing of historical equity gaps. For example, recent reports show Black and Hispanic children being identified at rates comparable to or slightly higher than White children for the first time, suggesting better access to diagnosis rather than overdiagnosis.

90/100 — the lab’s own confidence in the score above, not a second reading of the claim.

JAMA Network Openjournal · 95 · New England Journal of Medicinejournal · 95 · Centers for Disease Control and Prevention (CDC)gov · 98

• Diagnosis rates and referrals for ADHD and autism have risen sharply, while available epidemiological evidence suggests that underlying population prevalence has remained broadly stable. This divergence supports concern about possible misdiagnosis or overdiagnosis, particularly among adolescents and young adults.[2][5]
• A UK government review found that recorded diagnoses in some younger age groups now exceed older population-prevalence estimates and warned that the risk of misdiagnosis and overdiagnosis is becoming increasingly important.[2]
• The government review reported sharply rising diagnosis and referral activity, especially among adolescent and young adult females, despite no dramatic increase in estimated underlying ADHD prevalence.[5]

• The UK government review explicitly concluded that available evidence cannot establish overdiagnosis occurring at scale, partly because population-prevalence data and reporting are incomplete.[2]
• Rising diagnosis rates can reflect improved recognition of people previously missed, including girls and women, older people, and minoritized groups; experts cited by the Science Media Centre said autism and ADHD remain substantially underdiagnosed in several populations.[3]
• CDC surveillance documents increasing identified autism prevalence but does not establish that those diagnoses are inappropriate; diagnosis counts alone cannot distinguish genuine improved detection from overdiagnosis.[1][7]
• The evidence concerns different conditions, age groups, and health systems, so the broad statement that ADHD and autism are being overdiagnosed in children and young adults overgeneralizes a risk that has not been demonstrated consistently or at population scale.[2][3]

91/100 — the lab’s own confidence in the score above, not a second reading of the claim.

UK Department of Health and Social Caregov · 97 · UK Department of Health and Social Caregov · 97 · Science Media Centreother · 88 · U.S. Centers for Disease Control and Preventiongov · 98 · U.S. Centers for Disease Control and Preventiongov · 98 · ITV Newsnews · 85

• CDC data document sharp rises in identified prevalence (ADHD reaching ~11% of US children; autism 1 in 36 among 8-year-olds), increases too large and rapid to be explained solely by a true biological epidemic.
• Large geographic, racial/ethnic, and socioeconomic variation in diagnosis rates is more consistent with differing diagnostic thresholds, awareness, and incentives than with uniform underlying prevalence.
• Broadened criteria (especially autism spectrum including milder presentations), routine screening, school accommodations (IEPs/504 plans), and access to stimulants create incentives to label borderline, overlapping, or environmentally driven symptoms.
• Clinician reports, re-evaluation studies, and diagnostic-substitution research show some children and young adults receive ADHD or autism labels for typical developmental variation, sleep/trauma/anxiety issues, or other conditions.

• Much of the recorded increase reflects improved detection, reduced stigma, universal screening recommendations, and capture of previously missed cases (especially girls, milder presentations, and historically underserved groups).
• Both conditions show high heritability, replicated neurobiological correlates, and clear functional impairment in many diagnosed individuals; major medical bodies treat rising identification as a service need rather than primarily artifact.
• Documented historical underdiagnosis means current rates may be approaching, not exceeding, true prevalence in some populations; adult/young-adult ADHD diagnoses partly correct childhood misses.
• Treatment and educational supports produce measurable benefits for a substantial fraction of those diagnosed, inconsistent with a claim that most labels are false positives.

68/100 — the lab’s own confidence in the score above, not a second reading of the claim.

CDCgov · 95 · NIMHgov · 92 · CDCgov · 90